Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 8/20 | 0.62 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245606 | 0.87 | PIN1 (0.64) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL16014941 | 0.87 | PIN1 (0.67) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL16012720 | 0.87 | PIN1 (0.58) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL15145623 | 0.87 | PIN1 (0.70) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL16245594 | 0.84 | PIN1 (0.60) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL18869403 | 0.84 | PIN1 (0.59) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL16245543 | 0.81 | PIN1 (0.54) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL16245532 | 0.81 | PIN1 (0.53) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL16022206 | 0.80 | PIN1 (0.75) | PIN1GSK3BAURKAGSK3AMAPT | |
| SCHEMBL28877888 | 0.80 | PIN1 (0.79) | PIN1GSK3BAURKAGSK3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2964648-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2964649-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| WO-2014135244-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | EIF2AK4, GCN1, GTF2I | PIN1 2244/4885GSK3B 2810/4885AURKA 2203/4885 |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | EIF2AK4, GCN1, EIF4A2 | PIN1 1008/4885GSK3B 3045/4885AURKA 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.